SCHEMBL24723878

SCHEMBL24723878

CCc1cnc(C(C)=O)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
PARP1 P09874 1/20 0.37
CA12 O43570 3/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA6 P23280 3/20 0.36
CA7 P43166 3/20 0.36
CA13 Q8N1Q1 3/20 0.36
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 3/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9477821 0.82 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL17820124 0.82 ALDH1A1 (0.34) KDM4EL3MBTL1ALDH1A1KMT2AMAPT
SCHEMBL12524482 0.80 PARP1 (0.46) NPC1RAB9ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL25406160 0.80 ALDH1A1 (0.37) SMN1; SMN2KDM4EL3MBTL1CA1CA2
SCHEMBL17819455 0.80 ALDH1A1 (0.33) KDM4EL3MBTL1ALDH1A1KMT2AMAPT
SCHEMBL25738793 0.77 PLK1 (0.50) NPC1RAB9ASMN1; SMN2PARP1DEGS1
SCHEMBL12523424 0.77 CYP1A2 (0.44) KDM4ECA12CA1CA2CA7
SCHEMBL25406145 0.74 HSP90AB1 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL882970 0.73 APLNR (0.50) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL622903 0.72 L3MBTL1 (0.50) NPC1RAB9ASMN1; SMN2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 CN disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 NPC1 95/4885RAB9A 592/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.